Keytruda Before, After Surgery Improves Outcome in TNBC

(MedPage Today) -- Neoadjuvant pembrolizumab (Keytruda) plus chemotherapy, continued as a single agent after surgery, significantly improved event-free survival in patients with high-risk, early-stage triple-negative breast cancer (TNBC) in the...